Ratings Daewoong Co., Ltd.

Equities

A003090

KR7003090008

End-of-day quote Korea S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
19,900 KRW +1.12% Intraday chart for Daewoong Co., Ltd. +5.74% -3.63%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 432.34 for the 2024 fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-3.63% 596M -
+18.67% 43.74B
B-
+21.99% 22.26B
B+
+16.41% 14.9B -
+9.03% 13.39B
B+
+40.48% 12.12B
B
-9.64% 6.92B
B+
-0.05% 6.79B - -
-8.87% 5.73B - -
+12.41% 5.47B
B+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A003090 Stock
  4. Ratings Daewoong Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW